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Gastric cancer ranks the fourth most prevalent malignancy yet it is the second leading cause of cancer-related death. 
Every year, gastric cancer adds nearly 1 million new cancer cases, and 723,000 or 10% of cancer deaths to the global 
cancer burden. Approximately, 405,000 or 43% of the new cases and 325,000 or 45% of the deaths are in China, mak-
ing gastric cancer a particularly challenging malignancy. This thematic series discusses the molecular classifications 
of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the 
implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives 
on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immu-
notherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, 
and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.
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Gastric (including gastroesophageal junction, GEJ) can-
cer ranks the fourth most prevalent malignancy yet it is 
the second leading cause of cancer-related death world-
wide. Every year, gastric cancer adds nearly 1 million new 
cancer cases, and accounts for 10% of cancer deaths to 
the global cancer burden [1]. Approximately, 405,000 or 
43% of the new cases and 325,000 or 45% of gastric can-
cer-related deaths are in China, making gastric cancer a 
particularly challenging malignancy [1]. On the contrary, 
the overall incidence of gastric cancer in the western 
world has been steadily declining, except for GEJ can-
cer [2]. Because of the difference in disease prevalence 
between the developed and developing countries, gastric 
cancer has been a dormant indication in terms of basic 
research, translational medicine, as well as new drug 
development.
Surgery has remained as the only potential curative 
treatment option for early-stage gastric cancer. Over the 
past two decades, the surgical management of gastric 
cancer has evolved substantially. Shiozaki et al. [3] sum-
marized the key improvements in gastric cancer surgery 
in this period of time. Four key areas were investigated 
in carefully designed randomized controlled studies to 
include comparisons between D1 or D2 lymph node dis-
section in total or subtotal gastrectomy; gastrectomy with 
or without splenectomy or pancreatectomy along with 
D2 dissection; total or subtotal gastrectomy with or with-
out bursectomy; and the use of laparoscopic surgery in 
treating gastric cancer. Some of these trials assessed the 
impact of D1 versus D2 dissection on long-term survival. 
These studies provided critical evidence for surgeons to 
consider while selecting different surgical options based 
on individual patient conditions.
Unfortunately, the vast majority of patients with gastric 
cancer are either diagnosed with advanced unresectable 
or metastatic diseases or suffered with disease recur-
rence after initial surgical resection. In the era of targeted 
therapy, treatment of advanced-stage gastric cancer has 
been lagging behind. Chemotherapy remains as the only 
option for the majority of patients with moderate sur-
vival benefits. Two main intertwining causes underlie this 
unsatisfying situation: the lack of research and develop-
ment incentives by western pharmaceutical companies in 
this disease and the gaps in understanding of this com-
plex disease at the molecular biology level. As a disease 
that plaques population in developing world, gastric 
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cancer did not receive the same attention as other can-
cer types such as lung, breast, colorectal, and prostate 
cancers did. In the past two decades, only a few targeted 
drugs were tested in this disease. On the other hand, the 
slow pace in discovering novel therapeutics is in part due 
to the complexity of gastric cancer.
In recent years, we have witnessed substantial advance-
ment in research and development efforts in gastric 
cancer. The molecular characterization of gastric cancer 
paved the path for increased investment in finding effec-
tive treatments for this disease. Two articles in this series 
review the seminal work by the Asian Cancer Research 
Group (ACRG) [4] and by the Cancer Genome Atlas 
(TCGA) [5]. In contrary to the traditional pathological 
classification of gastric cancer into diffuse and intestinal 
subtypes, ACRG and TCGA use gene expression profile 
to classify gastric cancer into different subtypes based 
on common genomic alterations. These efforts began to 
provide a more comprehensive understanding of the high 
heterogeneity and diverse pathobiology of gastric cancer. 
These molecular data together with longitudinal clini-
cal data now divide gastric cancer into more distinctive 
subtypes. Each subtype carries a set of defined genomic 
alterations, and some of them are targetable. Such knowl-
edge enables more effective drug development based on 
personalized medicine approaches.
In the review article by Sun and Yan [6], recent 
advances in discovering and developing innovative can-
cer therapies were analyzed in the context of their poten-
tial influence in clinical management of advanced-stage 
gastric cancer. With the introduction of the first targeted 
therapy, e.g., trastuzumab [an anti-HER2 (v-erbB2 avian 
erythroblastic leukemia viral oncogene homolog 2) anti-
body], gastric cancer entered the era of personalized 
medicine following many other tumor types. Although 
only patients with strong HER2 overexpression or gene 
amplification benefit from this targeted treatment, it rep-
resents the first transformational change in gastric can-
cer treatment in two decades. Following trastuzumab, 
ramucirumab, a monoclonal antibody vascular endothe-
lia growth factor receptor-2 (VEGFR-2) antagonist, 
demonstrated survival benefits in both first- and second-
line treatment of gastric cancer. In parallel, apatinib, an 
oral small-molecule VEGFR-2 tyrosine kinase inhibitor 
(TKI), also significantly prolonged survival in patients 
with advanced gastric cancer whose disease progressed 
after first- or second-line chemotherapy treatment. More 
recently, anti-programmed cell death protein 1 (PD-1)/
programmed death-ligand 1 (PD-L1) immunotherapies 
are generating encouraging preliminary results either as 
monotherapy or in combination with chemotherapies in 
gastric cancer. It is anticipated that in the next few years, 
significant changes will be seen in the landscape of gastric 
cancer clinical treatment when multiple late-phase clini-
cal trials with these immunotherapies read out. Gastric 
cancer will enter into a new era of personalized medicine.
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